The company came through with about 38% operating margins this quarter, guiding 42% over the next couple of year. That's dramatic translation of top-line revenues to the bottom line.
While our macro view is bullish on small-cap biotech for 2006, we do not recommend indiscriminate buying.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.